We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.
- Authors
Sellem, Baptiste; Abdi, Basma; Lê, Minh; Tubiana, Roland; Valantin, Marc-Antoine; Seang, Sophie; Schneider, Luminita; Fayçal, Antoine; Peytavin, Gilles; Soulié, Cathia; Marcelin, Anne-Geneviève; Katlama, Christine; Pourcher, Valérie; Palich, Romain
- Abstract
In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV (PLHIV). We enrolled 85 patients who initiated intermittent B/F/TAF between 28 November 2018 and 30 July 2020: median (IQR) age 52 years (46–59), duration of virological suppression 9 years (3–13), CD4 633/mm3 (461–781). Median follow-up was 101 weeks (82–111). The virological success rate (no virological failure [VF]: confirmed plasma viral load [pVL] ≥ 50 copies/mL, or single pVL ≥ 200 copies/mL, or ≥50 copies/mL with ART change) was 100% (95%CI 95.8–100) and the strategy success rate (pVL < 50 copies/mL with no ART regimen change) was 92.9% (95%CI 85.3–97.4) at W48. Two VF occurred at W49 and W70, in 2 patients self-reporting poor compliance. No resistance mutation emerged at time of VF. Eight patients presented strategy discontinuation for adverse events. There was no significant change in the CD4 count, residual viraemia rate, neither body weight during follow-up, but a slight increase in CD4/CD8 ratio (p = 0.02). In conclusion, our findings suggest that B/F/TAF administered 5 or 4 days a week could maintain the control of HIV replication in virologically suppressed PLHIV while reducing cumulative exposition of ART.
- Subjects
HIV-positive persons; TENOFOVIR; RALTEGRAVIR; EMTRICITABINE; VIRAL load; CD4 lymphocyte count; BODY weight
- Publication
Journal of Personalized Medicine, 2023, Vol 13, Issue 4, p583
- ISSN
2075-4426
- Publication type
Article
- DOI
10.3390/jpm13040583